Danish drugmaker Genmab A/S saw its shares surge up to 14% on October 26, 2026, after reporting that its experimental ovarian cancer drug Rina-S cut the risk of death by 57% and disease progression by 71% in late-stage trials. Coupled with positive updates for its colorectal cancer candidate petosemtamab, analysts from JPMorgan and Jyske Bank raised their price targets. The pipeline breakthroughs offer critical long-term growth as Genmab prepares for expected patent expirations on its key royalty driver, Darzalex.
Rina-S clinical trial results
- ▪Genmab A/S reported that its experimental drug Rina-S cut the risk of disease progression or death by 71% in platinum-resistant ovarian cancer patients, meeting the late-stage trial's primary and key secondary endpoints
- ▪In a late-stage clinical trial for patients with platinum-resistant ovarian cancer, Genmab A/S's experimental drug Rina-S (rinatabart sesutecan) cut the risk of death by 57% compared to chemotherapy
Genmab stock market performance
- ▪Following the 23 October 2026 clinical trial results for Rina-S, Genmab A/S stock reached year-to-date gains of nearly 48%, making it Denmark's third-best performer on the C25 benchmark in 2026
- ▪Genmab A/S shares surged up to 14% in Copenhagen on October 26, 2026, marking the stock's largest single-day gain since March 2020
Analyst upgrades and price targets
- ▪Jyske Bank analyst Henrik Hallengreen Laustsen raised Genmab A/S's share price target by 24% to 2,925 kroner while maintaining a hold rating on October 26, 2026
- ▪JPMorgan upgraded Genmab A/S shares to overweight from neutral and raised its price target to 3,500 kroner following the positive Rina-S clinical trial data
Pipeline expansion and Darzalex royalties
- ▪Genmab A/S has been actively expanding its pipeline of cancer treatments to reduce reliance on royalty income generated by its blockbuster drug Darzalex
- ▪AL Sydbank senior analyst Soren Lontoft Hansen stated that the positive Rina-S trial results and petosemtamab pipeline developments could bridge Genmab A/S's revenue gap expected from expiring Darzalex royalties late in the decade
Story comments
Loading comments…